Omnicell Q4 2022 Earnings Report

Omnicell EPS Results

• Actual EPS: $0.02
• Consensus EPS: -$0.18
• Beat/Miss: Beat by +$0.20
• One Year Ago EPS: N/A

Omnicell Revenue Results

• Actual Revenue: $297.67 million
• Expected Revenue: $286.32 million
• Beat/Miss: Beat by +$11.35 million
• YoY Revenue Growth: N/A

Omnicell Announcement Details

• Quarter: Q4 2022
• Date: 2/28/2023
• Time: N/A

Omnicell (NASDAQ:OMCL), together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.